BioSpace News Archive

Aktis Oncology, a biotechnology company discovering and developing novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announces an oral presentation at the Oligonucleotide & Peptide Therapeutics Conference 2024, being held May 14-17, 2024, in Boston, Mass. and virtually.

Alcresta Therapeutics, Inc. today announced the commercial availability of the next-generation RELiZORB® (iMMOBILIZED LIPASE) cartridge.

Lucid Diagnostics Inc. today provided a business update for the Company and presented financial results for the three months ended March 31, 2024.

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi as shareholders, announced that Health Canada has granted approval for APRETUDE for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in at risk individuals who are HIV-1 negative.

Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, has announced the online publication of the one-year results of the DETOUR2 Trial in the Journal of Vascular Surgery.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent developments.

Delix Therapeutics today announced additional data from an ongoing Phase 1 trial evaluating DLX-001, a novel neuroplastogen, demonstrating evidence of brain activity in healthy volunteers without producing psychotomimetic, dissociative or hallucinogenic effects.

SÄPT today shared new data, presented by researchers this weekend, which showed that long-term efficacy was maintained for almost 2 years among adult patients participating in the LSD-Assist Study that investigated the efficacy and safety of LSD in the treatment of anxiety.

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced the launch of Twist Multiplexed Gene Fragments, pools of directly synthesized double-stranded DNA up to 500 base pairs in length with no limit on sequence number to enable high throughput screening applications.

TriLink BioTechnologies, a Maravai™ LifeSciences company and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery.